Bipolar Percutaneous Endocardial Septal Radiofrequency Ablation (Bi-PESA): First-in-Human Application for Hypertrophic Obstructive Cardiomyopathy

双极经皮心内膜间隔射频消融术(Bi-PESA):首次应用于肥厚型梗阻性心肌病的人体治疗

阅读:1

Abstract

BACKGROUND: Many patients with drug-refractory hypertrophic obstructive cardiomyopathy (HOCM) decline or are ineligible for surgical myectomy or alcohol septal ablation. Although conventional unipolar percutaneous endocardial septal radiofrequency ablation is a minimally invasive alternative, its limited lesion depth yields only modest left ventricular outflow tract gradient (LVOTG) relief. Bipolar radiofrequency catheter ablation creates deeper lesions in the treatment of ventricular arrhythmias; however, its role in HOCM remains unreported. FIRST-IN-HUMAN/EARLY REPORTS SUMMARY: We present the first in-human case of combined bipolar ablation and percutaneous endocardial septal radiofrequency ablation (Bi-PESA) in an older patient with drug-refractory HOCM. Ultimately, the patient experienced significant reduction in the LVOTG, translating to significant symptomatic improvement. DISCUSSION: This case suggests Bi-PESA could be a novel, effective, and safe septal reduction option for patients with drug-refractory HOCM. NOVELTY: To our knowledge, this is the first-in-human report of Bi-PESA for HOCM to reduce LVOTG and improve symptoms. TAKE-HOME MESSAGE: Bi-PESA may offer a feasible and potentially preferable alternative for patients with HOCM who decline or are ineligible for surgical myectomy or alcohol septal ablation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。